The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer

Authors

  • Adnan Budak Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey
  • Emine Budak Department of Nuclear Medicine, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey
  • Abdurrahman Hamdi Inan Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey
  • Ahkam Goksel Kanmaz Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey
  • Gokhan Tosun Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey
  • Emrah Beyan
  • Onur Suleyman Aldemir Clinic of Obstetrics and Gynecology, Private Cinarli Hospital, Izmir, Turkey
  • Alper Ileri Department of Obstetrics and Gynecology, Buca Seyfi Demirsoy Training and Research Hospital, Izmir, Turkey
  • Mehmet Ozeren Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey

Keywords:

CA125, epithelial ovarian cancer, FDG PET/CT, prognosis, survival

Abstract

Aim: To investigate the association between post treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) and post treatment cancer antigen 125 (CA125) results and overall survival (OS) of patients with epithelial ovarian cancer (EOC).
Material and Methods: Survival was analyzed with Kaplan-Meier, Log-Rank and Cox proportional-hazards regression analyses. All cases and PET+ cases were evaluated separately. In addition, PET and CA125 results were evaluated together in the overall case group, and a survival analysis was made for the four defined groups.
Results: The mean age of the 112 EOC-diagnosed patients was 54.9±0.9 years. Based on the PET/CT results, 48 patients were PET-and 64 patients were PET+; and 59 patients were CA125- and 53 patients were CA125+. In the overall case group, OS was found to be significantly shorter in advanced stage patients when compared to the early stage patients, in the CA125+ patients when compared to the CA125- patients, and in the PET+ patients when compared to the PET- patients. A univariate analysis revealed a significant association between stage, CA125 and PET results, and OS. In a multivariate analysis, the association between stage and CA125 with OS was maintained, although the PET results were not significant. When the PET and CA125 results were evaluated together, the OS was significantly shorter in the CA125+/PET+ group than in the CA125-/PET-and CA125-/PET+ groups. In the PET+ group, CA125 and the time from diagnosis to positive PET result were identified as independent prognostic factors.
Conclusion: Although OS had a tendency to be poorer in PET+ cases than negative cases, the PET results were not established as
an independent prognostic factor for survival. Our findings suggest that the post treatment CA125 value is more beneficial than PET
results for the estimation of prognosis in EOC.

Downloads

Published

2021-11-24

How to Cite

Budak, A., Budak, E., Inan, A. H., Kanmaz, A. G., Tosun, G., Beyan, E., Aldemir, O. S., Ileri, A., & Ozeren, M. (2021). The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer. Annals of Medical Research, 28(11), 1961–1966. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/3960

Issue

Section

Original Articles